A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Akebia Therapeutics Inc’s current trading price is -7.20% away from its 52-week high, while its distance from the 52-week low is 253.74%. The stock’s price range for this time frame has been between $1.07 and $4.08. The trading volume of the company’s shares in the Healthcare reached around 4.6 million for the day, which was evidently lower than the average daily volume of 4.78 million over the last three months.
Currently, the stock price of Akebia Therapeutics Inc (AKBA) is $3.79. In the most recent trading session, the stock underwent a significant upswing, peaking at $10.0 after opening at $3.79. The stock touched a low of $6.0 before closing at $3.72.
The market performance of Akebia Therapeutics Inc has been somewhat stable.
How Financial Performance Impacts Market Capitalization
Akebia Therapeutics Inc (AKBA) has experienced a quarterly rise of 63.15% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 994.08M and boasts a workforce of 181 employees.
Decoding Analysts’ Ratings for Akebia Therapeutics Inc
As of right now, 3 analysts are rating Akebia Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.94, with a change in price of +2.10. Similarly, Akebia Therapeutics Inc recorded 4,915,930 in trading volume during the last 100 days, posting a change of +123.96%.
How AKBA’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for AKBA stands at 8.39. Similarly, the long-term debt-to-equity ratio is also 7.41.
AKBA Stock Stochastic Average
Akebia Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 75.90%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 51.75%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 46.82% and 43.81%, respectively.
AKBA Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 202.80%. However, over the past six months, we’ve seen a weaker performance of 76.87%. The price of AKBA fallen by 2.02% over the last 30 days. And in the last five days, it has surged by 3.42%.
